EbsArgent® development
| Reference number | |
| Coordinator | Thioredoxin Systems AB |
| Funding from Vinnova | SEK 1 960 710 |
| Project duration | March 2022 - March 2024 |
| Status | Completed |
Important results from the project
At Enable-2, we have developed EbsArgent, an antibiotic candidate that combines silver and ebselen. This mixture has shown a strong synergistic antibacterial effect, which exceeds the effect of the individual substances. It has been shown to be effective against a range of bacterial strains, both Gram-positive and Gram-negative, including multidrug-resistant strains. In the project, the candidate has been developed towards preclinical studies with many good results.
Expected long term effects
We have by a good margin met the overall goals for the project, which have included characterizing EbsArgent as a leading antibacterial treatment with acceptable toxicological, ADMET and antibacterial activity profiles. The data generated has confirmed EbsArgent´s innovative mechanism of action and we have seen both tolerability and efficacy in studies in mice. We have developed formulations that allow higher dosages and received positive statements about continued preclinical development from several experts.
Approach and implementation
Enable-2 is a platform with an extensive network of experts. Through regular meetings with a large project group, we have received valuable guidance in the development work, based on broad and long experience in drug development. Our project partners have carried out various studies and participated in strategic discussions. Everyone´s participation in every step has led to faster and more well-founded decisions, which has made studies and activities both time- and cost-effective.